Conference Coverage

VIDEO: Sapien 3 TAVR bests surgery in intermediate-risk patients


 

AT ACC 16

References

The remarkable outcomes in regard to mortality and stroke are “clinically meaningful and some of the best outcomes we’ve ever witnessed with transcatheter therapy,” he said.

This study was funded by Edwards Lifesciences. Dr. Thourani disclosed that he has received consulting fees and/or research grants from Edwards Lifesciences, St. Jude Medical, Abbott Medical, Boston Scientific, Claret Medical, DirectFlow, Medtronic, and Sorin. Dr. Kandzari has received consultant fees and honoraria from Boston Scientific, The Medicines Company, and Medtronic.

The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel.

sworcester@frontlinemedcom.com

Pages

Recommended Reading

Study: Tricuspid annuloplasty with mitral replacement appeared safe and effective
MDedge Cardiology
Guideline update shortens minimum DAPT duration in CAD
MDedge Cardiology
Endovascular surges over surgery for patients hospitalized for CLI
MDedge Cardiology
VIDEO: PARTNER 2 results extend TAVR to intermediate-risk patients
MDedge Cardiology
TAVR matches surgery in intermediate-risk patients
MDedge Cardiology
Adding mitral valve repair to CABG found risky, with limited benefits
MDedge Cardiology
Self-expanding TAVR bests surgery based on 3-year stroke and death risks
MDedge Cardiology
VIDEO: STICHES trial update boosts CABG in ischemic cardiomyopathy
MDedge Cardiology
VIDEO: STICHES trial update boosts CABG in ischemic cardiomyopathy
MDedge Cardiology
Coronary bypass shows compelling advantages in ischemic cardiomyopathy
MDedge Cardiology